Gilead shares fall after FDA places clinical hold on HIV treatment trials

Gilead Sciences' shares fell as much as 4% after the FDA placed a clinical hold on trials for two investigational HIV drugs, GS-1720 and GS-4182, due to a drop in CD4+ T-cell counts in some patients. Jefferies analysts downplayed the impact, noting the hold is limited to a Phase II trial of a weekly oral combination pill and does not affect Gilead's PrEP program or other programs involving lenacapavir or integrase inhibitors, including injectable versions; they maintain a positive long-term outlook, citing Gilead's strong pipeline and potential to replace the Biktarvy franchise with long-acting injectables.

Analysis

Gilead Sciences (NASDAQ:GILD) shares experienced a notable decline, falling by as much as 4% and later trading down approximately 1.7% mid-morning Tuesday, subsequent to the US Food and Drug Administration (FDA) imposing a clinical hold on studies for two investigational HIV drugs, GS-1720 and GS-4182. This regulatory action stemmed from observed decreases in CD4+ T-cell counts and absolute lymphocyte counts in certain patients within a Phase II trial evaluating a weekly oral combination of these agents for HIV treatment, distinct from pre-exposure prophylaxis (PrEP). While Gilead affirmed its commitment to collaborating with regulators to address the concerns, Jefferies analysts characterized the development primarily as a "headline risk," maintaining a positive long-term outlook. The analysts highlighted that the hold is confined to this specific oral formulation and trial, and crucially, does not affect other Gilead programs involving lenacapavir (GS-4182 is a lenacapavir prodrug) or integrase inhibitors, including injectable versions, nor is it expected to impact the pivotal June 19 PDUFA date for lenacapavir-based PrEP. Jefferies reiterated confidence in Gilead's robust pipeline, particularly the transformative potential of long-acting injectable treatments aiming to replace the $15 billion Biktarvy franchise with a less frequent, twice-yearly regimen, underscoring a sustained positive long-term perspective despite the current setback for the specific oral combination.

Key Decisions for Investors

• Investors should monitor Gilead's progress in addressing the FDA's concerns regarding the clinical hold on GS-1720 and GS-4182, understanding that analysts currently view this as a limited issue affecting a specific oral combination trial.
• Attention should remain on the upcoming June 19 PDUFA date for lenacapavir-based PrEP, as its approval is a significant near-term catalyst and is not anticipated by Jefferies to be impacted by this particular clinical hold.
• Long-term investors should continue to evaluate Gilead based on the broader potential of its HIV pipeline, especially its long-acting injectable programs, which aim to significantly reshape the treatment landscape and potentially supersede major revenue drivers like Biktarvy.
• Consider whether the recent share price decline offers a strategic entry point, balancing the specific trial setback against the analyst-supported positive long-term outlook and broader pipeline strength, while acknowledging the inherent risks in pharmaceutical development.